Search

Your search keyword '"Pignata, Sandro"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Pignata, Sandro" Remove constraint Author: "Pignata, Sandro" Topic oncology Remove constraint Topic: oncology
29 results on '"Pignata, Sandro"'

Search Results

1. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial

2. Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

3. Ovarian Cancer Radiosensitivity: What Have We Understood So Far?

5. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.

6. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

7. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer--The GCIG Symptom Benefit Study.

8. In reply [8]

9. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.

10. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

11. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma.

12. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

13. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study

14. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy

15. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists

16. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

17. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

18. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer

19. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

20. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

21. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

22. BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories

23. PARP inhibitors in ovarian cancer

24. Trabectedin in Ovarian Cancer: is it now a Standard of Care?

25. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study

26. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

27. Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

28. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

29. Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer

Catalog

Books, media, physical & digital resources